CA2612481A1 - Stable pharmaceutical composition comprising linezolid form iv - Google Patents
Stable pharmaceutical composition comprising linezolid form iv Download PDFInfo
- Publication number
- CA2612481A1 CA2612481A1 CA002612481A CA2612481A CA2612481A1 CA 2612481 A1 CA2612481 A1 CA 2612481A1 CA 002612481 A CA002612481 A CA 002612481A CA 2612481 A CA2612481 A CA 2612481A CA 2612481 A1 CA2612481 A1 CA 2612481A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- linezolid
- linezolid form
- substantially free
- povidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical group O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 title claims abstract description 358
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 131
- 238000000034 method Methods 0.000 claims abstract description 74
- 239000007787 solid Substances 0.000 claims abstract description 29
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 76
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 66
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 61
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 61
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 59
- 229940069328 povidone Drugs 0.000 claims description 53
- 239000002904 solvent Substances 0.000 claims description 42
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 238000005469 granulation Methods 0.000 claims description 20
- 230000003179 granulation Effects 0.000 claims description 20
- 239000000594 mannitol Substances 0.000 claims description 16
- 238000005550 wet granulation Methods 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- 150000005846 sugar alcohols Chemical class 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 6
- 229960003907 linezolid Drugs 0.000 abstract description 81
- 238000002441 X-ray diffraction Methods 0.000 description 29
- 239000003826 tablet Substances 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 20
- 239000008187 granular material Substances 0.000 description 11
- 238000007908 dry granulation Methods 0.000 description 10
- 229910019142 PO4 Inorganic materials 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000007907 direct compression Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 5
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 5
- 238000000634 powder X-ray diffraction Methods 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229960001681 croscarmellose sodium Drugs 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- -1 chemically Chemical compound 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012254 powdered material Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000010996 solid-state NMR spectroscopy Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
A method of formulating a pharmaceutical composition comprising Form IV
sustancially free of linezolid Form II
and methods of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV sustantially free of linezolid Form II
sustancially free of linezolid Form II
and methods of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV sustantially free of linezolid Form II
Description
STABLE PHARMACEUTICAL COMPOSITION COMPRISING LINEZOLID FORM IV
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. provisional application no.
60/701,438, filed July 20, 2005, the contents of which are expressly incorporated herein.
FIELD OF THE INVENTION
The present invention is directed to a pharmaceutical composition containing linezolid form IV substantially free of linezolid form II.
The present invention is directed to a pharmaceutical composition containing linezolid form IV that does not substantially rearrange to linezolid form II.
The present invention is directed to a method of formulating linezolid to provide a pharmaceutical composition comprising linezolid wherein the linezolid is linezolid Form IV substantially free of linezolid Form II and methods of inhibiting the interconversion of linezolid Form IV into linezolid Form II wherein the method of manufacture is one that would normally occasion such interconversion, solid phannaceutical compositions comprising linezolid Form IV substantially free of linezolid Form II and stable solid pharmaceutical compositions comprising linezolid Form IV that do not substantially convert into linezolid Form II over time, methods of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV
substantially free of linezolid Form II, and methods of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV.
BACKGROUND
Linezolid, chemically, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide has the chemical structure:
O --~) N
O
H
O
Linezolid is an anti bacterial agent.
Linezolid is known to exist in different crystal forms. Linezolid Form II is described in US patent nos. US 6444813 and US 6559305. Linezolid Form II is characterized by its X-Ray powder diffraction pattern and IR peaks. Linezolid Form II is characterized by an X-Ray powder diffraction pattern with the following peaks:
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. provisional application no.
60/701,438, filed July 20, 2005, the contents of which are expressly incorporated herein.
FIELD OF THE INVENTION
The present invention is directed to a pharmaceutical composition containing linezolid form IV substantially free of linezolid form II.
The present invention is directed to a pharmaceutical composition containing linezolid form IV that does not substantially rearrange to linezolid form II.
The present invention is directed to a method of formulating linezolid to provide a pharmaceutical composition comprising linezolid wherein the linezolid is linezolid Form IV substantially free of linezolid Form II and methods of inhibiting the interconversion of linezolid Form IV into linezolid Form II wherein the method of manufacture is one that would normally occasion such interconversion, solid phannaceutical compositions comprising linezolid Form IV substantially free of linezolid Form II and stable solid pharmaceutical compositions comprising linezolid Form IV that do not substantially convert into linezolid Form II over time, methods of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV
substantially free of linezolid Form II, and methods of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV.
BACKGROUND
Linezolid, chemically, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide has the chemical structure:
O --~) N
O
H
O
Linezolid is an anti bacterial agent.
Linezolid is known to exist in different crystal forms. Linezolid Form II is described in US patent nos. US 6444813 and US 6559305. Linezolid Form II is characterized by its X-Ray powder diffraction pattern and IR peaks. Linezolid Form II is characterized by an X-Ray powder diffraction pattern with the following peaks:
2-theta relative intensity 7.10 2 9.54 9 13.88 6 14.23 24 16.18 3 16.79 100 17.69 2 19.41 4 19.69 2 19.93 6 21.61 15 22.39 23 22.84 4 23.52 7 24.16 1 25.28 13 26.66 1 27.01 3 27.77 1 It is reported that linezolid Form II can be obtained by crystallization in a variety of solvents including water, ethyl acetate, methanol, ethanol, propanol, isopropanol, butanol, acetonitrile, acetone, methyl ethyl ketone, chloroform, toluene, and xylene.
Another Form of linezolid, designated linezolid Form IV is described in WO
2005/035530 (denominated form III) and is characterized by X-Ray powder diffraction pattern having peaks at 7.6, 9.6, 13.6, 14.9, 18.2, 18.9, 21.2, 22.3, 25.6, 26.9, 27.9, and 29.9 degrees 2-theta. Linezolid Form IV can be obtained, for instance, by heating Form II at a temperature above about 90 C, for a period of between 2 aiid 12 hours.
Citation of any reference in this section of this application is not to be construed that such reference is prior art to the present application.
SUMMARY OF THE INVENTION
The invention relates to a pharmaceutical composition comprising polymorphically pure linezolid Form IV and a pharmaceutically acceptable excipient and to a method of making the pharmaceutical composition comprising polymorphically pure linezolid Form IV.
The invention also relates to a pharmaceutical composition comprising linezolid Form IV substantially free of linezolid form II and to a process for making the pharmaceutical composition comprising linezolid Form IV substantially free of linezolid form II.
The invention also relates to a phannaceutical composition comprising polymorphically stable linezolid Form IV and a pharmaceutically acceptable excipient and to a method for making the pharmaceutical composition comprising polymorphically stable linezolid Form IV.
Definitions of the terms "polymorphically pure," polymorphically stable," and "substantially free" are provided below. As defined below the stability of polymorphically stable linezolid Form IV may be defined in terms of stability at 25 C
and 60% relative humidity over a period of tiine or at 40 C and 75% relative humidity over a period of time. Preferably stability is defined with respect to 40 C
and 75%
Another Form of linezolid, designated linezolid Form IV is described in WO
2005/035530 (denominated form III) and is characterized by X-Ray powder diffraction pattern having peaks at 7.6, 9.6, 13.6, 14.9, 18.2, 18.9, 21.2, 22.3, 25.6, 26.9, 27.9, and 29.9 degrees 2-theta. Linezolid Form IV can be obtained, for instance, by heating Form II at a temperature above about 90 C, for a period of between 2 aiid 12 hours.
Citation of any reference in this section of this application is not to be construed that such reference is prior art to the present application.
SUMMARY OF THE INVENTION
The invention relates to a pharmaceutical composition comprising polymorphically pure linezolid Form IV and a pharmaceutically acceptable excipient and to a method of making the pharmaceutical composition comprising polymorphically pure linezolid Form IV.
The invention also relates to a pharmaceutical composition comprising linezolid Form IV substantially free of linezolid form II and to a process for making the pharmaceutical composition comprising linezolid Form IV substantially free of linezolid form II.
The invention also relates to a phannaceutical composition comprising polymorphically stable linezolid Form IV and a pharmaceutically acceptable excipient and to a method for making the pharmaceutical composition comprising polymorphically stable linezolid Form IV.
Definitions of the terms "polymorphically pure," polymorphically stable," and "substantially free" are provided below. As defined below the stability of polymorphically stable linezolid Form IV may be defined in terms of stability at 25 C
and 60% relative humidity over a period of tiine or at 40 C and 75% relative humidity over a period of time. Preferably stability is defined with respect to 40 C
and 75%
3 relative humidity over a period of tiine, preferably 3 months. It is preferred that the polyinorphically stable linezolid is polymorphically pure linezolid for IV.
Preferably, the polymorphically pure linezolid Form IV is substantially free, i.e., contains less thaii 20 %, of other polymorphic forms of linezolid, more preferably less than 20% of linezolid Form II. All further embodiments of the invention are described with reference to linezolid Form IV substantially free of linezolid Form II, but are equally applicable to the broader definition.
In one embodiment, the pharmaceutical composition is solid. In one embodiment, the pharmaceutical composition is in the form of a tablet. In one embodiment, the pharmaceutical composition is in the form of a capsule.
In one embodiment, the pharmaceutical composition comprises povidone.
In one embodiment, the pharmaceutical composition is substantially free of sugar alcohols In one embodiment, the pharmaceutical composition is substantially free of mannitol.
In one embodiment, the pharmaceutical compositions are prepared by wet granulation. In another embodiment the pharmaceutical compositions are prepared by dry granulation. In another enlbodiinent the pharmaceutical compositions are prepared by direct compression.
In one embodiment, the invention is directed to a method of preparing a pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II comprising wet granulating linezolid Form IV substantially free of linezolid Form II with a pharmaceutically acceptable excipient using a granulation solvent selected from the group consisting of water, isopropanol, and ethanol in the presence of povidone.
In one embodiment the method is directed to a method of preparing a pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II comprising wet granulating Form IV substantially free of linezolid Form II with an excipient that limits the ainount of linezolid Form IV that is converted
Preferably, the polymorphically pure linezolid Form IV is substantially free, i.e., contains less thaii 20 %, of other polymorphic forms of linezolid, more preferably less than 20% of linezolid Form II. All further embodiments of the invention are described with reference to linezolid Form IV substantially free of linezolid Form II, but are equally applicable to the broader definition.
In one embodiment, the pharmaceutical composition is solid. In one embodiment, the pharmaceutical composition is in the form of a tablet. In one embodiment, the pharmaceutical composition is in the form of a capsule.
In one embodiment, the pharmaceutical composition comprises povidone.
In one embodiment, the pharmaceutical composition is substantially free of sugar alcohols In one embodiment, the pharmaceutical composition is substantially free of mannitol.
In one embodiment, the pharmaceutical compositions are prepared by wet granulation. In another embodiment the pharmaceutical compositions are prepared by dry granulation. In another enlbodiinent the pharmaceutical compositions are prepared by direct compression.
In one embodiment, the invention is directed to a method of preparing a pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II comprising wet granulating linezolid Form IV substantially free of linezolid Form II with a pharmaceutically acceptable excipient using a granulation solvent selected from the group consisting of water, isopropanol, and ethanol in the presence of povidone.
In one embodiment the method is directed to a method of preparing a pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II comprising wet granulating Form IV substantially free of linezolid Form II with an excipient that limits the ainount of linezolid Form IV that is converted
4 to linezolid Form II. In one embodiment, the excipient that limits the amount of linezolid Form N that is converted to linezolid Form II is povidone. In one embodiment the invention is directed to a method of preparing a pharmaceutical composition comprising linezolid Form N substantially free of linezolid Form II
comprising wet granulating linezolid Form IV with an excipient that limits the amount of linezolid Form N that is converted to linezolid Form II and at least one other excipient. In one embodiment, the excipient that limits the amount of linezolid Form N that is converted to linezolid Form II is povidone.
In one embodiment, the pharmaceutical compositions are prepared by dry granulation. In one embodiment, the invention is directed to a method of preparing a pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II by dry granulating linezolid Form N with an excipient that liinits the ainount of linezolid Form IV that is converted to linezolid Form II. In one embodiment, the excipient that limits the amount of linezolid Form IV that is converted to linezolid Form II is povidone. In one einbodiment the invention is directed to a method of preparing a pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II comprising dry granulating linezolid Form IV with an excipient that limits the amount of linezolid Form N that is converted to linezolid Form II and at least one other excipient. In one embodiment, the excipient that limits the amount of linezolid Form N that is converted to linezolid Form II is povidone.
In another embodiment, the pharmaceutical coinpositions are prepared by direct compression. In one embodiment, the invention is directed to a method of preparing a pharmaceutical composition comprising linezolid Form IV
substantially free of linezolid Form II comprising admixing linezolid Form IV substantially free of linezolid Form II with a pharmaceutically acceptable excipient to provide a mixture and direct coinpressing the mixture. In one embodiment, the excipient is an excipient liinits the amount of linezolid Form N that is converted to linezolid Form II.
In one embodiment, the excipient that limits the amount of linezolid Form N that is converted to linezolid Form II is povidone. In one embodiment the invention is directed to a method of preparing a pharmaceutical composition comprising linezolid Form N substantially free of linezolid Form II comprising admixing linezolid Form IV substantially free of linezolid Form II with a pharmaceutically acceptable excipieiit that limits the amount of linezolid Form IV that is converted to linezolid Form II and at least one other excipient to provide a mixture and direct compressing the mixture.
In one embodiment, the excipient that limits the amount of linezolid Form IV
that is converted to linezolid Form II is povidone.
The invention further relates to a method of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical coinposition comprising linezolid form IV substantially free of linezolid Form II. In one embodiment, the solid pharmaceutical composition comprising linezolid form IV
substantially free of linezolid Form II is prepared according to the method of the invention. In one embodiment, the condition responsive to linezolid is a bacterial infection.
The invention further relates to a method of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV and povidone. In one embodiment, the condition responsive to linezolid is a bacterial infection.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is an XRD diffractogram of linezolid Form IV.
FIG. 2 is an XRD diffractogram of linezolid Form II.
FIG. 3 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 1.
FIG. 4 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 2.
FIG. 5 is an XRD diffractogram of the linezolid pharmaceutical coinposition prepared in Experiment No. 3.
FIG. 6 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 4.
FIG. 7 is an XRD diffractograin of the linezolid pharmaceutical composition prepared in Experiment No. 5.
FIG. 8 is an XRD diffractograin of the linezolid pharmaceutical composition prepared in Experiment No. 6.
FIG. 9 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 7.
FIG. 10 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 8.
FIG. 11 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 9.
FIG. 12 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 10.
FIG. 13 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 11.
FIG. 14 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 12.
FIG. 15 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 13.
FIG. 16 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 14.
FIG. 17 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 15.
. FIG. 18 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 16.
FIG. 19 is an XRD diffractogram of the linezolid phannaceutical composition prepared in Experiment No. 17.
FIG. 20 is an XRD diffractogram of the linezolid phannaceutical composition prepared in Experiment No. 18.
DETAILED DESCRIPTION OF TIIE INVENTION
The invention is directed to a method of preparing a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II.
The phrase "linezolid Form IV," as used herein means the polymorphic form of linezolid disclosed in W02005/035530 (and refered to in W02005/035530 as form III), the contents of which are herein incorporated in their entirety.
describes how this form of linezolid may be prepared for use in accordance with the present invention.
The phrase "solid dosage form" or "solid pharinaceutical composition," as used herein, means a dosage form that is a solid, i.e., not a liquid, and includes, but is not limited to, tablets, capsules, sugar coated tablets, film coated tablets, enteric coated tablets, inultiple compressed tablets, controlled release tablets, effervescent tablets, suppositories, and buccal and sublingual tablets (See, Remington Tlze Science and Practice of Pharmacy 20th ed. ("Remington"), edited by A. Gennaro, Philadelphia College of Pharmacy and Science 2000 (the contents of which are expressly incorporated herein by reference hereto), p. 858-856). The term "solid dosage form,"
as used herein, also includes suspensions of linezolid Form IV. The term "suspension," as used herein means a dispersion containing finely divided insoluble material suspended in a liquid medium (See, Remington, p. 317).
The phrase "excipient" or pharmaceutically acceptable excipient," as used herein, means an ingredient in a pharmaceutical composition other than the active ingredient (See, Remington, page 860). Excipients include, but are not limited to, diluents (inert substances to increase the bulk of the pharmaceutical composition), binders (agents used to impart cohesive qualities to a powdered material), lubricants (agents that prevent adhesion of material to a die or punch, reduce inter-particle friction, facilitate ejection of a tablet from a die cavity, and/or improve the rate of flow of a powder mixture), glidants (agents that improve the flow characteristics of a powder), disintegrants (agents that facilitate the breakup or disintegration of a tablet after administration), coloring agents (agents that impart a color to a dosage form), and flavoring agents (agents that impart a flavor to a dosage form) (See, Remington, page 860-863). Suitable excipients include, but are not limited to, those described in Remington (See, Remington, page 860-863).
The term "povidone," as used herein means polyvinylpyrrolidone.
The phrase "substantially free of," as used herein, ineans not more than 20%.
Accordingly, the phrase "linezolid Form IV substantially free of linezolid Form II"
means linezolid Form IV containing not more than 20% of linezolid Form II. In one embodiment, the linezolid Form IV contains not more than 15% of linezolid Form II.
In one embodiment, the linezolid Form IV contains not more than about 10% of linezolid Form II. In one embodiment, the linezolid Fonn IV contains not more than about 5% of linezolid Form II.
The plirase "polymorphically pure compound," as that term is used herein, means a polymorph of a compound that is substantially free of other polymorphs of the compound and the amorphous compound. Accordingly, the phrase "polymorphically pure linezolid Form IV" means linezolid Form IV that is substantially free of other polymorphs of linezolid and amorphous linezolid.
In one embodiment, the polymorphically pure linezolid Form IV contains not more than 20%
of other polymorphs of linezolid and ainorphous linezolid. In one embodiment, the polymorphically pure linezolid Form IV contains not more than 15% of other polymorphs of linezolid and amorphous linezolid. In one embodiment, the polymorphically pure linezolid Form IV contains not more than 10% of other polymorphs of linezolid and amorphous linezolid. In one embodiment, the polymorphically pure linezolid Form IV contains not more than 5% of other polymorphs of linezolid and amorphous linezolid.
The phrase "polymorphically stable linezolid form IV," as used herein, means linezolid form IV that shows not more than 10% conversion of linezolid Form IV
to linezolid Form II when stored at 25 C/60%RH for 3 months. In one embodiment, the linezolid form IV shows not more than 10% conversion of linezolid Form IV to linezolid Form II when stored at 25 C/60%RH for 6 months. In one embodiment, the linezolid form IV shows not more than 30% conversion of linezolid Form IV to linezolid Form II when stored at 40 C/75%RH for 3 months. In one embodiment, the linezolid form IV shows not more than 25% conversion of linezolid Form IV to linezolid Form II when stored at 40 C/75%RH for 3 months. In one embodiment, the linezolid form IV shows not more than 20% conversion of linezolid Form IV to linezolid Form II when stored at 40 C/75%RH for 3 months.
The phrase "wet granulation," as used herein, means a method of manufacturing a tablet that involves adding a binder to a mixture of the active ingredient and other excipients as a solution of the binder, and is well known to one of ordinary skill in the art (See, Remington, p. 865-868). Typically, wet granulation involves the steps of blending an active ingredient, in this case linezolid, with one or more solid excipients such as diluents and disintegrants to provide a powdered mix;
wetting the powdered mix with a granulation solvent or a solution of a binding agent in a granulation solvent to provide a damp mass; screening the dainp mass;
drying the damp mass to provide a dried mass; screening the dried mass to provide granules; and forming the granules into a solid dosage forin such as a capsule or tablet (See, Remington, page 865-868).
The phrase "dry granulation," as used herein, means a method of manufacturing a tablet that avoids the use of a granulation solvent and the step of drying, as is required by wet granulation, and is well known to one of ordinary skill in the art (See, Remington, page 869). Typically, dry granulation involves the steps of weighing, mixing, slugging or compressing, dry screening, lubrication, and compression (See, Remington, page 869).
The phrase "direct compression," as used herein, means a method of manufacturing a tablet by compressing tablets directly from powdered material without modifying the nature of the material itself, and is well known to one of ordinary skill in the art (See, Reinington, page 869-870).
In one embodiment, the pharmaceutical composition is in the fonn of a tablet.
In one embodiment, the phannaceutical composition is in the form of a capsule.
In one embodiment, the process involves the step of wet granulating linezolid Form IV substantially free of linezolid Form II with a pharmaceutically acceptable excipient using a granulation solvent selected from the group consisting of water, isopropanol, ethanol in the presence of povidone, and water admixed with isopropanol.
In one embodiment, the granulating solvent is substantially free of ethanol.
In one embodiment, the solvent comprises water. In one embodiment, the solvent is water substantially free of a second solvent. In one embodiment, the solvent is water.
In one embodiment, the solvent is ethanol in the presence of povidone.
In one embodiment, the solvent is water admixed with isopropanol.
In one embodiment, the solvent comprises isopropanol. In one embodiment, the solvent is isopropanol substantially free of a second solvent. In one embodiment, the solvent is isopropanol.
In one embodiment, the linezolid Form IV substantially free of linezolid Form II is wet granulated with more than one pharmaceutically acceptable excipient.
In one embodiment, povidone is a pharmaceutically acceptable excipient.
Water admixed with ethanol or isopropanol means a mixture of water and ethanol or isopropanol wherein the mixture contains greater than about 25%
water by weight, preferably greater than about 35% water by weight, more preferably greater than about 40% water by weight, and most preferably greater than about 50%
water by weight.
It has been observed that preparing a pharmaceutical composition comprising linezolid Form IV and a pharmaceutically acceptable excipient by wet granulating the linezolid Form IV and a pharmaceutically acceptable excipient using ethanol (not in the presence of povidone) as the granulation solvent, a common granulation solvent, the resulting pharmaceutical composition contains substantial amounts of linezolid Form II or transforms completely to form II.
By wet granulating the linezolid Form IV and pharmaceutically acceptable excipient with water, isopropanol, or ethanol with the presence of povidone to form the pharmaceutical composition, the conversion of linezolid Form IV to linezolid Form II is limited or even eliminated. The term "limited," as used herein, means that the amount of linezolid Forin IV converted to linezolid Form II is less than the amount of linezolid Form IV that would be converted to linezolid Form II if a pharmaceutical composition was prepared by wet granulating the linezolid Form IV
and pharmaceutically acceptable excipient with ethanol (not in the presence of povidone) as the granulation solvent.
The invention further relates to a method of preparing a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II
wherein the method comprises wet granulating linezolid Form IV substantially free of linezolid Form II with a phannaceutically acceptable excipient using a granulation solvent that is substantially free of ethanol.
In one embodiment, povidone is a pharmaceutically acceptable excipient.
Without wishing to be bound by theory, applicants suggest that linezolid Form IV is not more thermodynamically stable than linezolid Form II at room temperature.
Although solid linezolid Form IV is kinetically stable at room temperature, i.e., it does not convert to linezolid Form II (over a time period of at least 3 months at temperatures between 25 and 40 C), we have observed that when linezolid Form IV
is contacted with solvents, in particular ethanol, it readily transforms to linezolid Form II, i.e., the thermodynamically more stable form of linezolid at room temperature. As a consequence, pharmaceutical compositions comprising linezolid Form IV substantially free of linezolid Form II are difficult to prepare.
In one embodiment, the invention relates to means a method of manufacturing a pharmaceutical composition of linezolid form IV substantially free of linezolid form II, that avoids the use of a liquid during formulation.
It has also been observed that the conversion of linezolid Form IV to linezolid Form II can be limited by dry granulating linezolid Form IV with a pharmaceutically acceptable excipient. Accordingly, the invention further relates to a method of preparing a solid pharmaceutical composition comprising linezolid Form IV
substantially free of linezolid Form II wherein the method comprises dry granulating linezolid Fonn N substantially free of linezolid Fonn II with a pharmaceutically acceptable excipient.
In one embodiment, the linezolid Form IV substantially free of linezolid Forin II is dry granulated with more than one excipients.
In one embodiment, povidone is an excipient.
It has also been observed that the conversion of linezolid Form IV to linezolid Form II can be liinited by direct compression of linezolid Form IV with a pharmaceutically acceptable excipient. Accordingly, the invention further relates to a method of preparing a solid pharmaceutical coinposition comprising linezolid Form IV substantially free of linezolid Form II wherein the method comprises admixing linezolid Form IV substantially free of linezolid Form II with a pharmaceutically acceptable excipient to provide a mixture and direct compressing the mixture.
In one embodiment, the linezolid Form IV substantially free of linezolid Form II is admixed with more than one pharmaceutically acceptable excipient to provide a mixture and the mixture is then direct compressed.
In one embodiment, povidone is an excipient.
It has also been observed that specific excipients, called "excipients that preserve Form IV linezolid" limit the conversion of linezolid Form IV to linezolid Form II, even when the pharmaceutical composition is prepared by wet granulation with ethanol as the granulation solvent. Accordingly, the invention further relates to a method of preparing a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II wherein the method comprises admixing linezolid Form N substantially free of linezolid Form II with an excipient that preserves Form IV linezolid. The term "limit," as used herein, means that the amount of linezolid Form N converted to linezolid Form II is less than the amount of linezolid Form N that would be converted to linezolid Form II if a pharmaceutical composition was prepared by in the absence of excipients that preserve Form N
linezolid.
In one einbodiment, linezolid Form IV substantially free of linezolid Form II
is adinixed with an excipient that preserves Form IV linezolid and at least one other excipient to provide a inixture.
In one embodiment, the invention relates to a method of preparing a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II wherein the method comprises admixing linezolid Fonn IV
substantially free of linezolid Form II with an excipient that preserves Form IV
linezolid to provide a mixture and wet granulating the mixture using a solvent comprising ethanol as the granulating solvent. In one embodiment, the granulating solvent is ethanol.
An example of an excipient that preserves Form IV linezolid is povidone.
Accordingly, the invention further relates to a method of preparing a solid pharmaceutical composition coinprising linezolid Form IV substantially free of linezolid Form II wherein the method comprises admixing linezolid Forin IV
substantially free of linezolid Form II with povidone.
In one embodiment, the method involves admixing linezolid Form IV
substantially free of linezolid Form II, povidone, and at least one other pharmaceutically acceptable excipient.
In one embodiment, the linezolid Form IV substantially free of linezolid Form II is admixed with povidone by wet granulating the linezolid Form IV
substantially free of linezolid Form II and povidone. In one embodiment, the granulating solvent is ethanol. In one embodiment, the granulating solvent is ethanol admixed with water.
In one embodiment, the granulating solvent is isopropanol. In one embodiment, the granulating solvent is isopropanol admixed with water. In one embodiment, the granulating solvent is water.
In one embodiment, linezolid Form IV substantially free of linezolid Form II, povidone, and at least one other pharmaceutically acceptable excipient are admixed by wet granulation.
In one embodiment, the linezolid Form IV substantially free of linezolid Form II is admixed with povidone by dry granulation.
In one embodiment, the linezolid Form IV substantially free of linezolid Form II is admixed with povidone and at least other excipient by dry granulation.
In one embodiment, the pharmaceutical composition is obtained by admixing the linezolid Form IV substantially free of linezolid Form II and povidone to provide a mixture and direct compressing the mixture.
In one embodiment, the linezolid Form IV substantially free of linezolid Form II is admixed with povidone and at least other excipient to provide a mixture and direct compressing the mixture.
The invention further relates to a solid pharmaceutical coinposition comprising linezolid Form IV substantially free of linezolid Forin II.
The invention further relates to a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II and povidone.
In one einbodiment, the pharmaceutical composition is a tablet. In one embodiment, the pharmaceutical composition is a capsule. The solid pharmaceutical compositions are made using methods well known to those skilled in the art (See, Remington, p. 858-893).
The invention further relates to a method of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV substantially free of linezolid Form II. In one embodiment, the solid pharmaceutical composition comprising linezolid form IV
substantially free of linezolid Form II is prepared according to the method of the invention. In one embodiment, the condition responsive to linezolid is a bacterial infection.
The invention further relates to a method of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV and povidone. In one embodiment, the condition responsive to linezolid is a bacterial infection.
In each of the above-described embodiments of the invention, the composition is preferably substantially free of sugar alcohols such as mannitol.
EXAMPLES
Various pharmaceutical compositions, in the form of a tablet, containing 300 mg of linezolid Form IV, were prepared by wet granulation, dry granulation, or direct compression.
Examples 1-4 Method - Wet granulation.
Granulation Solution -Purified Water Procedure:
1. Mix together the components of part I.
2. Add granulation solution (Purified Water) to the mix from step 1 to form a granulate.
3. Dry and mill the granulate from step 2.
4. Add components of part II and III to the milled granulate from step 3 and mix to get a final blend.
comprising wet granulating linezolid Form IV with an excipient that limits the amount of linezolid Form N that is converted to linezolid Form II and at least one other excipient. In one embodiment, the excipient that limits the amount of linezolid Form N that is converted to linezolid Form II is povidone.
In one embodiment, the pharmaceutical compositions are prepared by dry granulation. In one embodiment, the invention is directed to a method of preparing a pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II by dry granulating linezolid Form N with an excipient that liinits the ainount of linezolid Form IV that is converted to linezolid Form II. In one embodiment, the excipient that limits the amount of linezolid Form IV that is converted to linezolid Form II is povidone. In one einbodiment the invention is directed to a method of preparing a pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II comprising dry granulating linezolid Form IV with an excipient that limits the amount of linezolid Form N that is converted to linezolid Form II and at least one other excipient. In one embodiment, the excipient that limits the amount of linezolid Form N that is converted to linezolid Form II is povidone.
In another embodiment, the pharmaceutical coinpositions are prepared by direct compression. In one embodiment, the invention is directed to a method of preparing a pharmaceutical composition comprising linezolid Form IV
substantially free of linezolid Form II comprising admixing linezolid Form IV substantially free of linezolid Form II with a pharmaceutically acceptable excipient to provide a mixture and direct coinpressing the mixture. In one embodiment, the excipient is an excipient liinits the amount of linezolid Form N that is converted to linezolid Form II.
In one embodiment, the excipient that limits the amount of linezolid Form N that is converted to linezolid Form II is povidone. In one embodiment the invention is directed to a method of preparing a pharmaceutical composition comprising linezolid Form N substantially free of linezolid Form II comprising admixing linezolid Form IV substantially free of linezolid Form II with a pharmaceutically acceptable excipieiit that limits the amount of linezolid Form IV that is converted to linezolid Form II and at least one other excipient to provide a mixture and direct compressing the mixture.
In one embodiment, the excipient that limits the amount of linezolid Form IV
that is converted to linezolid Form II is povidone.
The invention further relates to a method of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical coinposition comprising linezolid form IV substantially free of linezolid Form II. In one embodiment, the solid pharmaceutical composition comprising linezolid form IV
substantially free of linezolid Form II is prepared according to the method of the invention. In one embodiment, the condition responsive to linezolid is a bacterial infection.
The invention further relates to a method of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV and povidone. In one embodiment, the condition responsive to linezolid is a bacterial infection.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is an XRD diffractogram of linezolid Form IV.
FIG. 2 is an XRD diffractogram of linezolid Form II.
FIG. 3 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 1.
FIG. 4 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 2.
FIG. 5 is an XRD diffractogram of the linezolid pharmaceutical coinposition prepared in Experiment No. 3.
FIG. 6 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 4.
FIG. 7 is an XRD diffractograin of the linezolid pharmaceutical composition prepared in Experiment No. 5.
FIG. 8 is an XRD diffractograin of the linezolid pharmaceutical composition prepared in Experiment No. 6.
FIG. 9 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 7.
FIG. 10 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 8.
FIG. 11 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 9.
FIG. 12 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 10.
FIG. 13 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 11.
FIG. 14 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 12.
FIG. 15 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 13.
FIG. 16 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 14.
FIG. 17 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 15.
. FIG. 18 is an XRD diffractogram of the linezolid pharmaceutical composition prepared in Experiment No. 16.
FIG. 19 is an XRD diffractogram of the linezolid phannaceutical composition prepared in Experiment No. 17.
FIG. 20 is an XRD diffractogram of the linezolid phannaceutical composition prepared in Experiment No. 18.
DETAILED DESCRIPTION OF TIIE INVENTION
The invention is directed to a method of preparing a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II.
The phrase "linezolid Form IV," as used herein means the polymorphic form of linezolid disclosed in W02005/035530 (and refered to in W02005/035530 as form III), the contents of which are herein incorporated in their entirety.
describes how this form of linezolid may be prepared for use in accordance with the present invention.
The phrase "solid dosage form" or "solid pharinaceutical composition," as used herein, means a dosage form that is a solid, i.e., not a liquid, and includes, but is not limited to, tablets, capsules, sugar coated tablets, film coated tablets, enteric coated tablets, inultiple compressed tablets, controlled release tablets, effervescent tablets, suppositories, and buccal and sublingual tablets (See, Remington Tlze Science and Practice of Pharmacy 20th ed. ("Remington"), edited by A. Gennaro, Philadelphia College of Pharmacy and Science 2000 (the contents of which are expressly incorporated herein by reference hereto), p. 858-856). The term "solid dosage form,"
as used herein, also includes suspensions of linezolid Form IV. The term "suspension," as used herein means a dispersion containing finely divided insoluble material suspended in a liquid medium (See, Remington, p. 317).
The phrase "excipient" or pharmaceutically acceptable excipient," as used herein, means an ingredient in a pharmaceutical composition other than the active ingredient (See, Remington, page 860). Excipients include, but are not limited to, diluents (inert substances to increase the bulk of the pharmaceutical composition), binders (agents used to impart cohesive qualities to a powdered material), lubricants (agents that prevent adhesion of material to a die or punch, reduce inter-particle friction, facilitate ejection of a tablet from a die cavity, and/or improve the rate of flow of a powder mixture), glidants (agents that improve the flow characteristics of a powder), disintegrants (agents that facilitate the breakup or disintegration of a tablet after administration), coloring agents (agents that impart a color to a dosage form), and flavoring agents (agents that impart a flavor to a dosage form) (See, Remington, page 860-863). Suitable excipients include, but are not limited to, those described in Remington (See, Remington, page 860-863).
The term "povidone," as used herein means polyvinylpyrrolidone.
The phrase "substantially free of," as used herein, ineans not more than 20%.
Accordingly, the phrase "linezolid Form IV substantially free of linezolid Form II"
means linezolid Form IV containing not more than 20% of linezolid Form II. In one embodiment, the linezolid Form IV contains not more than 15% of linezolid Form II.
In one embodiment, the linezolid Form IV contains not more than about 10% of linezolid Form II. In one embodiment, the linezolid Fonn IV contains not more than about 5% of linezolid Form II.
The plirase "polymorphically pure compound," as that term is used herein, means a polymorph of a compound that is substantially free of other polymorphs of the compound and the amorphous compound. Accordingly, the phrase "polymorphically pure linezolid Form IV" means linezolid Form IV that is substantially free of other polymorphs of linezolid and amorphous linezolid.
In one embodiment, the polymorphically pure linezolid Form IV contains not more than 20%
of other polymorphs of linezolid and ainorphous linezolid. In one embodiment, the polymorphically pure linezolid Form IV contains not more than 15% of other polymorphs of linezolid and amorphous linezolid. In one embodiment, the polymorphically pure linezolid Form IV contains not more than 10% of other polymorphs of linezolid and amorphous linezolid. In one embodiment, the polymorphically pure linezolid Form IV contains not more than 5% of other polymorphs of linezolid and amorphous linezolid.
The phrase "polymorphically stable linezolid form IV," as used herein, means linezolid form IV that shows not more than 10% conversion of linezolid Form IV
to linezolid Form II when stored at 25 C/60%RH for 3 months. In one embodiment, the linezolid form IV shows not more than 10% conversion of linezolid Form IV to linezolid Form II when stored at 25 C/60%RH for 6 months. In one embodiment, the linezolid form IV shows not more than 30% conversion of linezolid Form IV to linezolid Form II when stored at 40 C/75%RH for 3 months. In one embodiment, the linezolid form IV shows not more than 25% conversion of linezolid Form IV to linezolid Form II when stored at 40 C/75%RH for 3 months. In one embodiment, the linezolid form IV shows not more than 20% conversion of linezolid Form IV to linezolid Form II when stored at 40 C/75%RH for 3 months.
The phrase "wet granulation," as used herein, means a method of manufacturing a tablet that involves adding a binder to a mixture of the active ingredient and other excipients as a solution of the binder, and is well known to one of ordinary skill in the art (See, Remington, p. 865-868). Typically, wet granulation involves the steps of blending an active ingredient, in this case linezolid, with one or more solid excipients such as diluents and disintegrants to provide a powdered mix;
wetting the powdered mix with a granulation solvent or a solution of a binding agent in a granulation solvent to provide a damp mass; screening the dainp mass;
drying the damp mass to provide a dried mass; screening the dried mass to provide granules; and forming the granules into a solid dosage forin such as a capsule or tablet (See, Remington, page 865-868).
The phrase "dry granulation," as used herein, means a method of manufacturing a tablet that avoids the use of a granulation solvent and the step of drying, as is required by wet granulation, and is well known to one of ordinary skill in the art (See, Remington, page 869). Typically, dry granulation involves the steps of weighing, mixing, slugging or compressing, dry screening, lubrication, and compression (See, Remington, page 869).
The phrase "direct compression," as used herein, means a method of manufacturing a tablet by compressing tablets directly from powdered material without modifying the nature of the material itself, and is well known to one of ordinary skill in the art (See, Reinington, page 869-870).
In one embodiment, the pharmaceutical composition is in the fonn of a tablet.
In one embodiment, the phannaceutical composition is in the form of a capsule.
In one embodiment, the process involves the step of wet granulating linezolid Form IV substantially free of linezolid Form II with a pharmaceutically acceptable excipient using a granulation solvent selected from the group consisting of water, isopropanol, ethanol in the presence of povidone, and water admixed with isopropanol.
In one embodiment, the granulating solvent is substantially free of ethanol.
In one embodiment, the solvent comprises water. In one embodiment, the solvent is water substantially free of a second solvent. In one embodiment, the solvent is water.
In one embodiment, the solvent is ethanol in the presence of povidone.
In one embodiment, the solvent is water admixed with isopropanol.
In one embodiment, the solvent comprises isopropanol. In one embodiment, the solvent is isopropanol substantially free of a second solvent. In one embodiment, the solvent is isopropanol.
In one embodiment, the linezolid Form IV substantially free of linezolid Form II is wet granulated with more than one pharmaceutically acceptable excipient.
In one embodiment, povidone is a pharmaceutically acceptable excipient.
Water admixed with ethanol or isopropanol means a mixture of water and ethanol or isopropanol wherein the mixture contains greater than about 25%
water by weight, preferably greater than about 35% water by weight, more preferably greater than about 40% water by weight, and most preferably greater than about 50%
water by weight.
It has been observed that preparing a pharmaceutical composition comprising linezolid Form IV and a pharmaceutically acceptable excipient by wet granulating the linezolid Form IV and a pharmaceutically acceptable excipient using ethanol (not in the presence of povidone) as the granulation solvent, a common granulation solvent, the resulting pharmaceutical composition contains substantial amounts of linezolid Form II or transforms completely to form II.
By wet granulating the linezolid Form IV and pharmaceutically acceptable excipient with water, isopropanol, or ethanol with the presence of povidone to form the pharmaceutical composition, the conversion of linezolid Form IV to linezolid Form II is limited or even eliminated. The term "limited," as used herein, means that the amount of linezolid Forin IV converted to linezolid Form II is less than the amount of linezolid Form IV that would be converted to linezolid Form II if a pharmaceutical composition was prepared by wet granulating the linezolid Form IV
and pharmaceutically acceptable excipient with ethanol (not in the presence of povidone) as the granulation solvent.
The invention further relates to a method of preparing a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II
wherein the method comprises wet granulating linezolid Form IV substantially free of linezolid Form II with a phannaceutically acceptable excipient using a granulation solvent that is substantially free of ethanol.
In one embodiment, povidone is a pharmaceutically acceptable excipient.
Without wishing to be bound by theory, applicants suggest that linezolid Form IV is not more thermodynamically stable than linezolid Form II at room temperature.
Although solid linezolid Form IV is kinetically stable at room temperature, i.e., it does not convert to linezolid Form II (over a time period of at least 3 months at temperatures between 25 and 40 C), we have observed that when linezolid Form IV
is contacted with solvents, in particular ethanol, it readily transforms to linezolid Form II, i.e., the thermodynamically more stable form of linezolid at room temperature. As a consequence, pharmaceutical compositions comprising linezolid Form IV substantially free of linezolid Form II are difficult to prepare.
In one embodiment, the invention relates to means a method of manufacturing a pharmaceutical composition of linezolid form IV substantially free of linezolid form II, that avoids the use of a liquid during formulation.
It has also been observed that the conversion of linezolid Form IV to linezolid Form II can be limited by dry granulating linezolid Form IV with a pharmaceutically acceptable excipient. Accordingly, the invention further relates to a method of preparing a solid pharmaceutical composition comprising linezolid Form IV
substantially free of linezolid Form II wherein the method comprises dry granulating linezolid Fonn N substantially free of linezolid Fonn II with a pharmaceutically acceptable excipient.
In one embodiment, the linezolid Form IV substantially free of linezolid Forin II is dry granulated with more than one excipients.
In one embodiment, povidone is an excipient.
It has also been observed that the conversion of linezolid Form IV to linezolid Form II can be liinited by direct compression of linezolid Form IV with a pharmaceutically acceptable excipient. Accordingly, the invention further relates to a method of preparing a solid pharmaceutical coinposition comprising linezolid Form IV substantially free of linezolid Form II wherein the method comprises admixing linezolid Form IV substantially free of linezolid Form II with a pharmaceutically acceptable excipient to provide a mixture and direct compressing the mixture.
In one embodiment, the linezolid Form IV substantially free of linezolid Form II is admixed with more than one pharmaceutically acceptable excipient to provide a mixture and the mixture is then direct compressed.
In one embodiment, povidone is an excipient.
It has also been observed that specific excipients, called "excipients that preserve Form IV linezolid" limit the conversion of linezolid Form IV to linezolid Form II, even when the pharmaceutical composition is prepared by wet granulation with ethanol as the granulation solvent. Accordingly, the invention further relates to a method of preparing a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II wherein the method comprises admixing linezolid Form N substantially free of linezolid Form II with an excipient that preserves Form IV linezolid. The term "limit," as used herein, means that the amount of linezolid Form N converted to linezolid Form II is less than the amount of linezolid Form N that would be converted to linezolid Form II if a pharmaceutical composition was prepared by in the absence of excipients that preserve Form N
linezolid.
In one einbodiment, linezolid Form IV substantially free of linezolid Form II
is adinixed with an excipient that preserves Form IV linezolid and at least one other excipient to provide a inixture.
In one embodiment, the invention relates to a method of preparing a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II wherein the method comprises admixing linezolid Fonn IV
substantially free of linezolid Form II with an excipient that preserves Form IV
linezolid to provide a mixture and wet granulating the mixture using a solvent comprising ethanol as the granulating solvent. In one embodiment, the granulating solvent is ethanol.
An example of an excipient that preserves Form IV linezolid is povidone.
Accordingly, the invention further relates to a method of preparing a solid pharmaceutical composition coinprising linezolid Form IV substantially free of linezolid Form II wherein the method comprises admixing linezolid Forin IV
substantially free of linezolid Form II with povidone.
In one embodiment, the method involves admixing linezolid Form IV
substantially free of linezolid Form II, povidone, and at least one other pharmaceutically acceptable excipient.
In one embodiment, the linezolid Form IV substantially free of linezolid Form II is admixed with povidone by wet granulating the linezolid Form IV
substantially free of linezolid Form II and povidone. In one embodiment, the granulating solvent is ethanol. In one embodiment, the granulating solvent is ethanol admixed with water.
In one embodiment, the granulating solvent is isopropanol. In one embodiment, the granulating solvent is isopropanol admixed with water. In one embodiment, the granulating solvent is water.
In one embodiment, linezolid Form IV substantially free of linezolid Form II, povidone, and at least one other pharmaceutically acceptable excipient are admixed by wet granulation.
In one embodiment, the linezolid Form IV substantially free of linezolid Form II is admixed with povidone by dry granulation.
In one embodiment, the linezolid Form IV substantially free of linezolid Form II is admixed with povidone and at least other excipient by dry granulation.
In one embodiment, the pharmaceutical composition is obtained by admixing the linezolid Form IV substantially free of linezolid Form II and povidone to provide a mixture and direct compressing the mixture.
In one embodiment, the linezolid Form IV substantially free of linezolid Form II is admixed with povidone and at least other excipient to provide a mixture and direct compressing the mixture.
The invention further relates to a solid pharmaceutical coinposition comprising linezolid Form IV substantially free of linezolid Forin II.
The invention further relates to a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II and povidone.
In one einbodiment, the pharmaceutical composition is a tablet. In one embodiment, the pharmaceutical composition is a capsule. The solid pharmaceutical compositions are made using methods well known to those skilled in the art (See, Remington, p. 858-893).
The invention further relates to a method of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV substantially free of linezolid Form II. In one embodiment, the solid pharmaceutical composition comprising linezolid form IV
substantially free of linezolid Form II is prepared according to the method of the invention. In one embodiment, the condition responsive to linezolid is a bacterial infection.
The invention further relates to a method of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV and povidone. In one embodiment, the condition responsive to linezolid is a bacterial infection.
In each of the above-described embodiments of the invention, the composition is preferably substantially free of sugar alcohols such as mannitol.
EXAMPLES
Various pharmaceutical compositions, in the form of a tablet, containing 300 mg of linezolid Form IV, were prepared by wet granulation, dry granulation, or direct compression.
Examples 1-4 Method - Wet granulation.
Granulation Solution -Purified Water Procedure:
1. Mix together the components of part I.
2. Add granulation solution (Purified Water) to the mix from step 1 to form a granulate.
3. Dry and mill the granulate from step 2.
4. Add components of part II and III to the milled granulate from step 3 and mix to get a final blend.
5. Compress the final blend into tablets.
Table 1 Ingredients Example 1 Example 2 Example 3 Example 4 m tab mg/tab mg/tab m tab Part I
Linezolid 300.0 300.0 300.0 300.0 Starch NF 100.0 100.0 100.0 100.0 Lactose Monohydrate NF 100.0 ----- ----- -----Mannitol ----- ----- ----- 100.0 Cal. Phosphate Dibasic Anhyd. ----- 100.0 100.0 -----USP
Povidone USP (PVP K-30) ---- ----- 30.0 -----Hydroxy Methyl Cellulose NF 16.0 16.0 ----- 16.0 Croscarmellose Sodium NF ---- ----- 24.0 -----Crospovidone USP 24.0 24.0 ----- 24.0 Part II
Lactose Spray Dried 54.0 ----- ----- 54.0 Microcrystalline Cellulose NF ----- ----- 40.0 -----A-Tab (Cal. Phosphate Dibasic ----- 54.0 ----- -----Anhyd. USP) Part III
Magnesium Stearate NF 6.0 6.0 6.0 6.0 Total 600.0 600.0 600.0 600.0 Examples 5-8 Method -Wet granulation Granulation Solution - Ethanol Procedure:
1. Mix together the components of part I.
2. Add granulation solution (Ethanol ) to the mix from step I to form a granulate.
3. Dry and mill the granulate from step 2.
4. Add components of part II and III to the milled granulate from step 3 and mix to get a final blend.
5. Compress the final blend into tablets.
Table 2 Ingredients Example 5 Example 6 Example 7 Example 8 mg/tab mg/tab m tab mg/tab Part I
Linezolid 300.0 300.0 300.0 300.0 Starch NF 100.0 100.0 100.0 100.0 Lactose Monohydrate NF 100.0 ----- ----- -----Cal. Phosphate Dibasic Anhyd. ----- 100.0 100.0 -----USP
Mannitol ----- ----- ----- 100.0 Povidone USP (PVP K-30) ---- ----- 30.0 -----Hydroxy Methyl Cellulose NF 16.0 16.0 ----- 16.0 Croscarmellose Sodium NF ---- ----- 24.0 -----Cros ovidone USP 24.0 24.0 ----- 24.0 Part II
Lactose Spray Dried 54.0 ----- ----- 54.0 Microcrystalline Cellulose NF ------ ----- 40.0 -----A-Tab (Cal. Phosphate Dibasic ----- 54.0 ----- -----Anhyd. USP) Part III
Magnesium Stearate NF 6.0 6.0 6.0 6.0 Total = 600.0 600.0 600.0 600.0 Examples 9-12 Metlzod - Direct Compression Procedure:
1. Mix together the components of part I.
2. Add Magnesiuin Stearate of Part II to the mix from step 1 and mix to get a final mix.
3. Compress the final mix from step 2 into tablets.
Table 3 Ingredients Example Example Example Example mg/tab m/tab mg/tab mg/tab Part I
Linezolid 300.0 300.0 300.0 300.0 Starch 1500 100.0 100.0 100.0 100.0 Mannitol ----- ----- ----- 200.0 Povidone USP (PVP K-30) 30.0 ----- 30.0 30.0 Hydroxy Methyl Cellulose NF ---- 30.0 ----- -----Croscarmellose Sodium NF ---- 24.0 ----- -----Cros ovidone USP 24.0 ----- 24.0 24.0 Lactose Spray Dried 100.0 ----- ----- -----Microcrystalline Cellulose NF 140.0 40.0 240.0 40.0 A-Tab (Cal. Phosphate Dibasic ----- 200.0 ----- -----Anhyd. USP) Part II
Magnesium Stearate NF 6.0 6.0 6.0 6.0 Total 700.0 700.0 700.0 700.0 Examples 13-14 Method - Dry Granulation.
Procedure:
1. Mix together the components of Part I and II.
2. Compress the mix from step 1 into tablets (slugs).
3. Mill the tablets from step 2, add components of part III and IV, and mix well to get a final blend.
4. Compress the final blend from step 3 into tablets.
Table 4 Ingredients Example 13 Example 14 mg/tab mg/tab Part I
Linezolid 300.0 300.0 Starch NF 100.0 100.0 Mannitol ----- 100.0 Povidone USP (PVP K-30) 30.0 -----Hydroxy Methyl Cellulose NF ---- 16.0 A-Tab (Cal. Phosphate Dibasic Anhyd. USP) 100.0 -----Cros ovidone USP 24.0 24.0 Part II
Magnesium Stearate NF 5.0 5.0 Part III
Mannitol ----- 150 A-Tab (Cal. Phosphate Dibasic Anhyd. USP) 136.0 -----Part IV
Magnesium Stearate NF 5.0 5.0 Total 700.0 700.0 Examples 15-18 Method - Wet granulation.
Granulation Solution - See table below Procedure:
1. Mix together the components of part I.
2. Add the granulation solution and mix to form a granulate.
3. Dry wet granulate from step 2 and mill.
4. Add components of part II and III to the milled granulate from step 3 and mix to get a final blend.
5. Compress the final blend from step 4 into tablets.
Table 5 Ingredients Example 15 Example Example Example 18 mg/tab 16 17 mg/tab mg/tab mg/tab Part I
Linezolid 300.0 300.0 300.0 300.0 Starch NF 100.0 100.0 100.0 100.0 Cal. Phosphate Dibasic 100.0 100.0 100.0 -----Anhyd. USP
Mannitol ----- ----- ----- 100.0 Povidone USP (PVP K-30) 30.0 30.0 30.0 30.0 Hydroxy Methyl Cellulose ----- ----- ----- -----NF
Croscarmellose Sodium NF ---- ----- ----- -----Cros ovidone USP 24.0 24.0 24.0 24.0 Granulation Solution Ethanol/Purified iso-propyl PVP K-30 PVP K-30 in Water alcohol in Alcohol Alcohol/Purified 1:1 Water 1:1 Part II
Microcrystalline Cellulose 40.0 40.0 40.0 40.0 NF
Part III
Magnesium Stearate NF 6.0 6.0 6.0 6.0 Total 600.0 600.0 600.0 600.0 The polymorphic content of each of the pharmaceutical compositions was determined by x-ray powder diffraction ("XRD"). XRD diffractograms were obtained using a Scintag X-Ray powder diffractometer model X'TRA with a Cu tube and a solid state detector. For sampling a round standard aluminum sample holder with a round zero background quartz plate was used. The following scanning parameters were used: Regular scan, i.e., 2-40 degrees 20, continuous scan, rate 3.00 degree/min.
FIG. 1 depicts the XRD diffractogram of linezolid Form IV and FIG. 2 depicts the XRD diffractogram of linezolid Form II.
The characteristic pealcs in the XRD diffractogram of linezolid Form II are found at about 7.1 0.2, 9.6 0.2, 14.2 0.2, 16.9 0.2, 21.7 0.2, 22.5 0.2, and 23.6 0.2 degrees 2-theta.
The characteristic peaks in the XRD diffractogram of linezolid Form IV are found at about 7.4 0.2, 9.4 0.2, 13.6 0.2, 14.8 0.2, 15.2 0.2, 15.4 0.2, 16.3 0.2, 16.9 0.2,18.0 0.2, 18.5 0.2, 18.8 0.2,21.0 0.2,22.3 0.2,and29.7 0.2 degrees 2-theta.
FIGS. 3-20 depict the XRD diffractogram of the pharmaceutical compositions prepared above. By knowing the characteristic peaks in the XRD of linezolid Form II
and linezolid Form IV it is possible to determine the crystal Form of the linezolid in each pharmaceutical composition. The XRD diffractogram of the pharmaceutical compositions includes peaks from the linezolid and the excipients included in the pharmaceutical forinulation. By knowing which peaks in the XRD diffractogram of the pharmaceutical composition are due to the excipients, it is possible to identify the peaks that are due to linezolid and, therefore, to identify whether the linezolid in the pharmaceutical composition is linezolid Form IV or linezolid Form II.
Although, it may not be possible in an XRD diffractogram of a pharmaceutical composition to identify every one of the characteristic peaks of linezolid Form II or linezolid Form IV identified above (for example, because peaks from an excipient may interfere with or overlap with peaks from linezolid), a sufficient number of peaks corresponding to linezolid Form IV or linezolid Form II can be identified for one of ordinary skill in the art to characterize the linezolid in the pharmaceutical composition as linezolid Form IV or linezolid Form II. Typically, the occurrence of peaks in the XRD
diffractogram of a pharmaceutical composition at 7.4, 9.4, 13.6, 18.0, 21.0 degrees 2-theta ( 0.2) is sufficient to show that the linezolid present in the pharmaceutical composition is linezolid Form IV Similarly, the occurrence of peaks in the XRD diffractogram of a pharmaceutical composition at 14.2,, 21.7, 23.6 degrees 2-theta ( 0.2) is sufficient to show that the linezolid present in the pharmaceutical composition in addition to form IV is linezolid Form II. The choice of the specific peaks, however, may vary if the excipients used will be different.
Techniques other than X-ray powder diffraction, well lcnown to those of , ordinary skill in the art, can also be used to identify and quantify polymorphs in pharmaceutical compositions such as tablets. Representative other methods include, but are not limited to, solid-state NMR and infra-red spectroscopy.
Table 6 summarizes the crystal Form of the linezolid in each of the pharmaceutical compositions upon manufacture.
~
N +
~
-I O
w ~
~ 0 a\
cn . w +
w d-w OC) w oo ;4 y~o C) M + o ~ H
o O O
w w ~w +
o o m w 'n en ph W ~I~ ,~s+ v~
L7 vr ~ U W w Table 7 summarizes the peaks of the active ingredient detected in the X-Ray diffractograms of the tablets.
Table 7 Number of XRD peaks of the active ingredient detected in the diffractograms of the tablets experiment 1 Peaks of Form IV at about 7.4, 9.4, 13.6, 18.1, 18.5, 22.2 degrees 2-theta 2 Peaks of Form IV at about 7.4, 9.4, 13.5, 15.2-15.5 (broad), 16.3, 16.9, 18.0, 18.5, 18.7, 21.1, 22.3 degrees 2-theta 3' Peaks of Form IV at about 7.5, 9.5, 13.6, 15.3-15.5 (broad), 16.4, 17.0, 18.1, 18.6, 18.9 (shoulder), 21.1, 22.4 degrees 2-theta 4 Peaks of Form IV at about 7.4, 9.4, 13.6, 14.7, 15.1-15.4 (broad), 16.9, 18.0, 18.5, 21.0, 22.3 degrees 2-theta Peaks of Form II at about 9.5, 14.2, 16.9, 22.4, 23.6, 21.6, 25.2 degrees 2-theta
Table 1 Ingredients Example 1 Example 2 Example 3 Example 4 m tab mg/tab mg/tab m tab Part I
Linezolid 300.0 300.0 300.0 300.0 Starch NF 100.0 100.0 100.0 100.0 Lactose Monohydrate NF 100.0 ----- ----- -----Mannitol ----- ----- ----- 100.0 Cal. Phosphate Dibasic Anhyd. ----- 100.0 100.0 -----USP
Povidone USP (PVP K-30) ---- ----- 30.0 -----Hydroxy Methyl Cellulose NF 16.0 16.0 ----- 16.0 Croscarmellose Sodium NF ---- ----- 24.0 -----Crospovidone USP 24.0 24.0 ----- 24.0 Part II
Lactose Spray Dried 54.0 ----- ----- 54.0 Microcrystalline Cellulose NF ----- ----- 40.0 -----A-Tab (Cal. Phosphate Dibasic ----- 54.0 ----- -----Anhyd. USP) Part III
Magnesium Stearate NF 6.0 6.0 6.0 6.0 Total 600.0 600.0 600.0 600.0 Examples 5-8 Method -Wet granulation Granulation Solution - Ethanol Procedure:
1. Mix together the components of part I.
2. Add granulation solution (Ethanol ) to the mix from step I to form a granulate.
3. Dry and mill the granulate from step 2.
4. Add components of part II and III to the milled granulate from step 3 and mix to get a final blend.
5. Compress the final blend into tablets.
Table 2 Ingredients Example 5 Example 6 Example 7 Example 8 mg/tab mg/tab m tab mg/tab Part I
Linezolid 300.0 300.0 300.0 300.0 Starch NF 100.0 100.0 100.0 100.0 Lactose Monohydrate NF 100.0 ----- ----- -----Cal. Phosphate Dibasic Anhyd. ----- 100.0 100.0 -----USP
Mannitol ----- ----- ----- 100.0 Povidone USP (PVP K-30) ---- ----- 30.0 -----Hydroxy Methyl Cellulose NF 16.0 16.0 ----- 16.0 Croscarmellose Sodium NF ---- ----- 24.0 -----Cros ovidone USP 24.0 24.0 ----- 24.0 Part II
Lactose Spray Dried 54.0 ----- ----- 54.0 Microcrystalline Cellulose NF ------ ----- 40.0 -----A-Tab (Cal. Phosphate Dibasic ----- 54.0 ----- -----Anhyd. USP) Part III
Magnesium Stearate NF 6.0 6.0 6.0 6.0 Total = 600.0 600.0 600.0 600.0 Examples 9-12 Metlzod - Direct Compression Procedure:
1. Mix together the components of part I.
2. Add Magnesiuin Stearate of Part II to the mix from step 1 and mix to get a final mix.
3. Compress the final mix from step 2 into tablets.
Table 3 Ingredients Example Example Example Example mg/tab m/tab mg/tab mg/tab Part I
Linezolid 300.0 300.0 300.0 300.0 Starch 1500 100.0 100.0 100.0 100.0 Mannitol ----- ----- ----- 200.0 Povidone USP (PVP K-30) 30.0 ----- 30.0 30.0 Hydroxy Methyl Cellulose NF ---- 30.0 ----- -----Croscarmellose Sodium NF ---- 24.0 ----- -----Cros ovidone USP 24.0 ----- 24.0 24.0 Lactose Spray Dried 100.0 ----- ----- -----Microcrystalline Cellulose NF 140.0 40.0 240.0 40.0 A-Tab (Cal. Phosphate Dibasic ----- 200.0 ----- -----Anhyd. USP) Part II
Magnesium Stearate NF 6.0 6.0 6.0 6.0 Total 700.0 700.0 700.0 700.0 Examples 13-14 Method - Dry Granulation.
Procedure:
1. Mix together the components of Part I and II.
2. Compress the mix from step 1 into tablets (slugs).
3. Mill the tablets from step 2, add components of part III and IV, and mix well to get a final blend.
4. Compress the final blend from step 3 into tablets.
Table 4 Ingredients Example 13 Example 14 mg/tab mg/tab Part I
Linezolid 300.0 300.0 Starch NF 100.0 100.0 Mannitol ----- 100.0 Povidone USP (PVP K-30) 30.0 -----Hydroxy Methyl Cellulose NF ---- 16.0 A-Tab (Cal. Phosphate Dibasic Anhyd. USP) 100.0 -----Cros ovidone USP 24.0 24.0 Part II
Magnesium Stearate NF 5.0 5.0 Part III
Mannitol ----- 150 A-Tab (Cal. Phosphate Dibasic Anhyd. USP) 136.0 -----Part IV
Magnesium Stearate NF 5.0 5.0 Total 700.0 700.0 Examples 15-18 Method - Wet granulation.
Granulation Solution - See table below Procedure:
1. Mix together the components of part I.
2. Add the granulation solution and mix to form a granulate.
3. Dry wet granulate from step 2 and mill.
4. Add components of part II and III to the milled granulate from step 3 and mix to get a final blend.
5. Compress the final blend from step 4 into tablets.
Table 5 Ingredients Example 15 Example Example Example 18 mg/tab 16 17 mg/tab mg/tab mg/tab Part I
Linezolid 300.0 300.0 300.0 300.0 Starch NF 100.0 100.0 100.0 100.0 Cal. Phosphate Dibasic 100.0 100.0 100.0 -----Anhyd. USP
Mannitol ----- ----- ----- 100.0 Povidone USP (PVP K-30) 30.0 30.0 30.0 30.0 Hydroxy Methyl Cellulose ----- ----- ----- -----NF
Croscarmellose Sodium NF ---- ----- ----- -----Cros ovidone USP 24.0 24.0 24.0 24.0 Granulation Solution Ethanol/Purified iso-propyl PVP K-30 PVP K-30 in Water alcohol in Alcohol Alcohol/Purified 1:1 Water 1:1 Part II
Microcrystalline Cellulose 40.0 40.0 40.0 40.0 NF
Part III
Magnesium Stearate NF 6.0 6.0 6.0 6.0 Total 600.0 600.0 600.0 600.0 The polymorphic content of each of the pharmaceutical compositions was determined by x-ray powder diffraction ("XRD"). XRD diffractograms were obtained using a Scintag X-Ray powder diffractometer model X'TRA with a Cu tube and a solid state detector. For sampling a round standard aluminum sample holder with a round zero background quartz plate was used. The following scanning parameters were used: Regular scan, i.e., 2-40 degrees 20, continuous scan, rate 3.00 degree/min.
FIG. 1 depicts the XRD diffractogram of linezolid Form IV and FIG. 2 depicts the XRD diffractogram of linezolid Form II.
The characteristic pealcs in the XRD diffractogram of linezolid Form II are found at about 7.1 0.2, 9.6 0.2, 14.2 0.2, 16.9 0.2, 21.7 0.2, 22.5 0.2, and 23.6 0.2 degrees 2-theta.
The characteristic peaks in the XRD diffractogram of linezolid Form IV are found at about 7.4 0.2, 9.4 0.2, 13.6 0.2, 14.8 0.2, 15.2 0.2, 15.4 0.2, 16.3 0.2, 16.9 0.2,18.0 0.2, 18.5 0.2, 18.8 0.2,21.0 0.2,22.3 0.2,and29.7 0.2 degrees 2-theta.
FIGS. 3-20 depict the XRD diffractogram of the pharmaceutical compositions prepared above. By knowing the characteristic peaks in the XRD of linezolid Form II
and linezolid Form IV it is possible to determine the crystal Form of the linezolid in each pharmaceutical composition. The XRD diffractogram of the pharmaceutical compositions includes peaks from the linezolid and the excipients included in the pharmaceutical forinulation. By knowing which peaks in the XRD diffractogram of the pharmaceutical composition are due to the excipients, it is possible to identify the peaks that are due to linezolid and, therefore, to identify whether the linezolid in the pharmaceutical composition is linezolid Form IV or linezolid Form II.
Although, it may not be possible in an XRD diffractogram of a pharmaceutical composition to identify every one of the characteristic peaks of linezolid Form II or linezolid Form IV identified above (for example, because peaks from an excipient may interfere with or overlap with peaks from linezolid), a sufficient number of peaks corresponding to linezolid Form IV or linezolid Form II can be identified for one of ordinary skill in the art to characterize the linezolid in the pharmaceutical composition as linezolid Form IV or linezolid Form II. Typically, the occurrence of peaks in the XRD
diffractogram of a pharmaceutical composition at 7.4, 9.4, 13.6, 18.0, 21.0 degrees 2-theta ( 0.2) is sufficient to show that the linezolid present in the pharmaceutical composition is linezolid Form IV Similarly, the occurrence of peaks in the XRD diffractogram of a pharmaceutical composition at 14.2,, 21.7, 23.6 degrees 2-theta ( 0.2) is sufficient to show that the linezolid present in the pharmaceutical composition in addition to form IV is linezolid Form II. The choice of the specific peaks, however, may vary if the excipients used will be different.
Techniques other than X-ray powder diffraction, well lcnown to those of , ordinary skill in the art, can also be used to identify and quantify polymorphs in pharmaceutical compositions such as tablets. Representative other methods include, but are not limited to, solid-state NMR and infra-red spectroscopy.
Table 6 summarizes the crystal Form of the linezolid in each of the pharmaceutical compositions upon manufacture.
~
N +
~
-I O
w ~
~ 0 a\
cn . w +
w d-w OC) w oo ;4 y~o C) M + o ~ H
o O O
w w ~w +
o o m w 'n en ph W ~I~ ,~s+ v~
L7 vr ~ U W w Table 7 summarizes the peaks of the active ingredient detected in the X-Ray diffractograms of the tablets.
Table 7 Number of XRD peaks of the active ingredient detected in the diffractograms of the tablets experiment 1 Peaks of Form IV at about 7.4, 9.4, 13.6, 18.1, 18.5, 22.2 degrees 2-theta 2 Peaks of Form IV at about 7.4, 9.4, 13.5, 15.2-15.5 (broad), 16.3, 16.9, 18.0, 18.5, 18.7, 21.1, 22.3 degrees 2-theta 3' Peaks of Form IV at about 7.5, 9.5, 13.6, 15.3-15.5 (broad), 16.4, 17.0, 18.1, 18.6, 18.9 (shoulder), 21.1, 22.4 degrees 2-theta 4 Peaks of Form IV at about 7.4, 9.4, 13.6, 14.7, 15.1-15.4 (broad), 16.9, 18.0, 18.5, 21.0, 22.3 degrees 2-theta Peaks of Form II at about 9.5, 14.2, 16.9, 22.4, 23.6, 21.6, 25.2 degrees 2-theta
6 Peaks of Form II at about 9.5, 14.2, 16.2, 16.8, 19.4, 21.7, 22.4,23.6, 25.3 degrees 2-theta
7. Peaks of Form IV at about 7.4, 9.4, 13.6, 18.1, 18.5, 18.8 (shoulder), 21.0, 22.3 and peak of Form II at about 14.2, 23.6 degrees 2-theta.
8 Peaks of Form II at about 9.6, 14.3, 16.9, 21.8, 22.5, 23.7 degrees 2-theta.
9 Peaks of Form IV at about 7.5, 9.5, 13.6, 16.9, 18.1, 18.5, 21.0, 22.3 degrees 2-theta Peaks of Form IV at about 7.5, 9.5, 13.6, 16.4, 16.9, 18.1, 18.5, 18.8, 21.1, 22.3, 25.5degrees 2-theta 11 Peaks of Form IV at about 7.4, 9.4, 13.6, 15.1-15.4 (broad), 16.4, 16.9, 18.0, 18.5, 21.0, 22.2 degrees 2-theta 12 Peaks of Form IV at about 7.4, 9.5, 13.7, 16.4, 16.9, 18.2, 18.8, 25.3, 25.5 degrees 2-theta and peak of Form II at about 23.6 degrees 2-theta.
13 Peaks of Form IV at about7.4, 9.4, 13.6, 15.2-15.5 (broad), 16.9,18.1, 18.5, 21.0, 22.2 degrees 2-theta 14 Peaks of Form IV at about 7.5, 9.5, 14.7, 15.1-15.5 (broad), 16.4, 16.9, 18.1, 18.5, 18.9 (shoulder), 21.1, 22.3 degrees 2-theta and peak of Form II at about 23.5 degrees 2-theta.
Peaks of Form IV at about7.4, 9.4, 13.5, 15.2-15.5 (broad), 16.3, 16.9,18.1, 18.5, 21.1, 22.2 degrees 2-theta and peak of Form II at about 9.7, 14.4, 23.6 degrees 2-theta.
16 Peaks of Form IV at about 7.4, 9.4, 13.6, 15.1-15.5 (broad), 16.3, 16.9, 18.1, 18.5, 21.1, 22.3 degrees 2-theta.
17 Peaks of Form IV at about 7.5, 9.5, 13.6, 15.2-15.5 (broad), 16.4, 17.0, 18.2, 18.6, 21.1, 22.3 degrees 2-theta and peak of Form II at about 23.6 degrees 2-theta.
1 S Pealcs of Form IV at about 7.3, 9.4, 13.5, 15.3-15.5 (broad), 18.0, 18.5, 21.0, 22.2 degrees 2-theta and peak of Form II at about 14.2, 21.7, 23.4 degrees 2-theta.
All the formulations, disregarding the polymorphic composition, were extremely stable at 25 C/60%RH for 6 or 3 months, in the sense that NMT 10%
conversion of Form IV to Form II occurred. (See Table 8).
+ +
~ O
+
~
.
~
+ ~
+
wz ~
~
wz ~
wz + +
N rm rA wz wz ~
a\
a a ~
c=, a + ~
o o ~ o H
It was observed that all the solid compositions prepared according to the methods of the invention by wet granulating with water, isopropanol, or ethanol in the presence of povidone are stable at 40 C/75%RH (See tables 9 and 10), according to the following criteria:
Not more than 30% conversion of linezolid Form IV to linezolid Form II after 3 months (ex. 4, 7, 9, 11, 15, 17, 18);
Not more than 25% conversion of linezolid Form IV to linezolid Form II after 2 months (ex. 4, 7, 9, 11, 12, 15, 17, 18);
Not more than 20% conversion of linezolid Form IV to linezolid Form II after 1 month (ex., 7, 9, 10, 11, 15, 17, 18).
Table 9: Stability results of Form IV formulations at 40 C/75%RH (no detectable conversion to Form II) Interval Example Example Example Example No.1 No.2 No.3 No.16 T=0 IV IV IV IV
T=lMonth IV IV IV IV
T=2Months IV IV IV IV
T=3Months IV IV IV IV
The results in Table 9 show that there is no detectable conversion of Form VI
to Form II in the compositions of Examples 1, 2, 3, and 16..
G) \ o= o o 0~0 1 + "0 +
w 0 O
^~' ~ o o y U
;.~
z' 0 .'., o 0 cd c$
o 0 0 0 -- -- -- -- ~ 0 ` 4-~
Q-1 m o 0 0 = r, ~ v]
~ OC) z a~ o 0 0 0 0 ~ N v) kn O O
- -4 _1 It tn S~ ^
o M p~
0 o O N
O
o U o o ' o ~ o ~ cl o w z E
t4.
~
o 0 O tn "O ~ w + . . .
z on N t'n 0 0 4-4 z Cd o 0 cn E- E-The results of the above described experiments demonstrate the following:
Wet granulation with water or isopropanol is better than granulation with ethanol to provide a formulation with Form IV substantially free of Form II.
Wet granulation with ethanol containing povidone is better than granulation with ethanol in the absence of povidone to provide a formulation with Form IV
substantially free of Form II.
Povidone inhibits the conversion of Form IV to Form II even under conditions were the conversion of Form IV to Form II is likely (e.g., in the presence of ethanol). Formulating a pllarmaceutical containing povidone by adding the povidone to the composition as a solution of povidone is better than admixing solid povidone with other excipients.
Wet granulation advantageously provides a formulation with Form IV
substantially free of Form II.
Dry granulation advantageously provides a formulation with Form IV
substantially free of Form II.
It is advantageous to avoid using sugar alcohols, in particular mannitol, as an excipient. Even in dry granulation methods it is advantageous to avoid using sugar alcohols, in particular mannitol, as an excipient.
The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments that are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.
A number of references have been cited, the entire disclosure of which are incorporated herein by reference.
13 Peaks of Form IV at about7.4, 9.4, 13.6, 15.2-15.5 (broad), 16.9,18.1, 18.5, 21.0, 22.2 degrees 2-theta 14 Peaks of Form IV at about 7.5, 9.5, 14.7, 15.1-15.5 (broad), 16.4, 16.9, 18.1, 18.5, 18.9 (shoulder), 21.1, 22.3 degrees 2-theta and peak of Form II at about 23.5 degrees 2-theta.
Peaks of Form IV at about7.4, 9.4, 13.5, 15.2-15.5 (broad), 16.3, 16.9,18.1, 18.5, 21.1, 22.2 degrees 2-theta and peak of Form II at about 9.7, 14.4, 23.6 degrees 2-theta.
16 Peaks of Form IV at about 7.4, 9.4, 13.6, 15.1-15.5 (broad), 16.3, 16.9, 18.1, 18.5, 21.1, 22.3 degrees 2-theta.
17 Peaks of Form IV at about 7.5, 9.5, 13.6, 15.2-15.5 (broad), 16.4, 17.0, 18.2, 18.6, 21.1, 22.3 degrees 2-theta and peak of Form II at about 23.6 degrees 2-theta.
1 S Pealcs of Form IV at about 7.3, 9.4, 13.5, 15.3-15.5 (broad), 18.0, 18.5, 21.0, 22.2 degrees 2-theta and peak of Form II at about 14.2, 21.7, 23.4 degrees 2-theta.
All the formulations, disregarding the polymorphic composition, were extremely stable at 25 C/60%RH for 6 or 3 months, in the sense that NMT 10%
conversion of Form IV to Form II occurred. (See Table 8).
+ +
~ O
+
~
.
~
+ ~
+
wz ~
~
wz ~
wz + +
N rm rA wz wz ~
a\
a a ~
c=, a + ~
o o ~ o H
It was observed that all the solid compositions prepared according to the methods of the invention by wet granulating with water, isopropanol, or ethanol in the presence of povidone are stable at 40 C/75%RH (See tables 9 and 10), according to the following criteria:
Not more than 30% conversion of linezolid Form IV to linezolid Form II after 3 months (ex. 4, 7, 9, 11, 15, 17, 18);
Not more than 25% conversion of linezolid Form IV to linezolid Form II after 2 months (ex. 4, 7, 9, 11, 12, 15, 17, 18);
Not more than 20% conversion of linezolid Form IV to linezolid Form II after 1 month (ex., 7, 9, 10, 11, 15, 17, 18).
Table 9: Stability results of Form IV formulations at 40 C/75%RH (no detectable conversion to Form II) Interval Example Example Example Example No.1 No.2 No.3 No.16 T=0 IV IV IV IV
T=lMonth IV IV IV IV
T=2Months IV IV IV IV
T=3Months IV IV IV IV
The results in Table 9 show that there is no detectable conversion of Form VI
to Form II in the compositions of Examples 1, 2, 3, and 16..
G) \ o= o o 0~0 1 + "0 +
w 0 O
^~' ~ o o y U
;.~
z' 0 .'., o 0 cd c$
o 0 0 0 -- -- -- -- ~ 0 ` 4-~
Q-1 m o 0 0 = r, ~ v]
~ OC) z a~ o 0 0 0 0 ~ N v) kn O O
- -4 _1 It tn S~ ^
o M p~
0 o O N
O
o U o o ' o ~ o ~ cl o w z E
t4.
~
o 0 O tn "O ~ w + . . .
z on N t'n 0 0 4-4 z Cd o 0 cn E- E-The results of the above described experiments demonstrate the following:
Wet granulation with water or isopropanol is better than granulation with ethanol to provide a formulation with Form IV substantially free of Form II.
Wet granulation with ethanol containing povidone is better than granulation with ethanol in the absence of povidone to provide a formulation with Form IV
substantially free of Form II.
Povidone inhibits the conversion of Form IV to Form II even under conditions were the conversion of Form IV to Form II is likely (e.g., in the presence of ethanol). Formulating a pllarmaceutical containing povidone by adding the povidone to the composition as a solution of povidone is better than admixing solid povidone with other excipients.
Wet granulation advantageously provides a formulation with Form IV
substantially free of Form II.
Dry granulation advantageously provides a formulation with Form IV
substantially free of Form II.
It is advantageous to avoid using sugar alcohols, in particular mannitol, as an excipient. Even in dry granulation methods it is advantageous to avoid using sugar alcohols, in particular mannitol, as an excipient.
The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments that are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.
A number of references have been cited, the entire disclosure of which are incorporated herein by reference.
Claims (37)
1. A pharmaceutical composition comprising polymorphically stable linezolid Form IV and a pharmaceutically acceptable excipient.
2. The pharmaceutical composition of claim 1, wherein the excipient is povidone.
3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is substantially free of mannitol.
4. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a solid.
5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is in the form of a tablet or a capsule.
6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition shows less than 30 percent conversion of linezolid Form IV to linezolid Form II when the pharmaceutical composition is maintained at 40° C
and 75% relative humidity for 3 months.
and 75% relative humidity for 3 months.
7. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition shows less than 25 percent conversion of linezolid Form IV to linezolid Form II when the pharmaceutical composition is maintained at 40° C
and 75% relative humidity for 2 months.
and 75% relative humidity for 2 months.
8. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition shows less than 20 percent conversion of linezolid Form IV to linezolid Form II when the pharmaceutical composition is maintained at 40° C
and 75% relative humidity for 1 months.
and 75% relative humidity for 1 months.
9. A pharmaceutical composition comprising polymorphically pure linezolid Form IV and a pharmaceutically acceptable excipient.
The pharmaceutical composition of claim 9, wherein the linezolid Form IV is polymorphically stable linezolid Form IV.
11. A pharmaceutical composition comprising linezolid Form IV
substantially free of linezolid Form II and a pharmaceutically acceptable excipient.
substantially free of linezolid Form II and a pharmaceutically acceptable excipient.
12. The pharmaceutical composition of claim 11, wherein the linezolid Form IV is polymorphically stable linezolid Form IV.
13. A pharmaceutical composition comprising linezolid Form IV and a pharinaceutically acceptable excipient, wherein the pharmaceutically acceptable excipient is an excipient that limits the conversion of linezolid Form IV to Form II.
14. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition is substantially free of linezolid Form II.
The pharmaceutical composition of claim 13, wherein the excipient is povidone.
16. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition is substantially free of mannitol.
17. A method of manufacturing a pharmaceutical composition comprising linezolid Form IV comprising wet granulating linezolid Form IV with a pharmaceutically acceptable excipient using a granulating solvent that is substantially free of ethanol.
18. The method of claim 17, wherein the linezolid Form IV is substantially free of linezolid Form II.
19. The method of claim 17, wherein the granulating solvent selected from the group consisting of water and isopropanol.
20. The method of claim 17, wherein the pharmaceutically acceptable excipient comprises povidone.
21. A method of manufacturing a pharmaceutical composition comprising linezolid Form IV comprising wet granulating linezolid Form IV with a pharmaceutically acceptable excipient using a granulating solvent selected from the group consisting of water, isopropanol, or ethanol in the presence of povidone.
22. The method of claim 21, wherein the linezolid Form IV is substantially free of linezolid Form II.
23. The method of claim 21, wherein the granulating solvent comprises water substantially free of ethanol.
24. The method of claim 21, wherein the granulating solvent comprises isopropanol substantially free of ethanol.
25. The method of claim 21, wherein the granulating solvent comprises ethanol in the presence of povidone.
26. A method of manufacturing a pharmaceutical composition comprising linezolid Form IV comprising dry granulating linezolid form IV with a pharmaceutically acceptable excipient.
27 The method of claim 26, wherein the linezolid Form IV is substantially free of linezolid Form II.
28. The method of claim 26, wherein the pharmaceutically acceptable excipient comprises povidone.
29. A method of manufacturing a pharmaceutical composition comprising linezolid Form IV comprising admixing linezolid form IV with a pharmaceutically acceptable excipient to provide a mixture and direct compressing the mixture.
30. The method of claim 29, wherein the linezolid Form IV is substantially free of linezolid Form II.
31. The method of claim 29, wherein the pharmaceutically acceptable excipient comprises povidone.
32. A method of limiting the conversion of linezolid Form IV to linezolid Form II during formulation of a pharmaceutical composition comprising linezolid Form IV and a pharmaceutically acceptable excipient or of limiting the conversion of linezolid Form IV to linezolid Form II in the pharmaceutical composition comprising at least one of:
i. formulating the pharmaceutical composition by wet granulation using a granulating solvent that is substantially free of ethanol;
ii. formulating the pharmaceutical composition by wet granulation using a granulating solvent, wherein during formulation the granulating solvent contacts the linezolid Form IV in the presence of povidone;
iii. including povidone in the pharmaceutical composition; and iv. keeping the pharmaceutical composition substantially free of sugar alcohols.
i. formulating the pharmaceutical composition by wet granulation using a granulating solvent that is substantially free of ethanol;
ii. formulating the pharmaceutical composition by wet granulation using a granulating solvent, wherein during formulation the granulating solvent contacts the linezolid Form IV in the presence of povidone;
iii. including povidone in the pharmaceutical composition; and iv. keeping the pharmaceutical composition substantially free of sugar alcohols.
33. The method of claim 32, wherein the method comprises formulating the pharmaceutical composition by wet granulation using a granulating solvent that is substantially free of ethanol and the granulation solvent is selected from the group consisting of water and isopropanol.
34. The method of claim 32, wherein the method comprises keeping the pharmaceutical composition substantially free of sugar alcohols and the sugar alcohol is mannitol.
35. The method of claim 17, wherein the method comprises keeping the pharmaceutical composition substantially free of sugar alcohols and the sugar alcohol is mannitol.
36. The method of claim 26, wherein the method comprises keeping the pharmaceutical composition substantially free of sugar alcohols and the sugar alcohol is mannitol.
37. The method of claim 29, wherein the method comprises keeping the pharmaceutical composition substantially free of sugar alcohols and the sugar alcohol is mannitol.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70143805P | 2005-07-20 | 2005-07-20 | |
US60/701,438 | 2005-07-20 | ||
PCT/US2006/001514 WO2007018588A1 (en) | 2005-07-20 | 2006-01-17 | Stable pharmaceutical composition comprising linezolid form iv |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2612481A1 true CA2612481A1 (en) | 2007-02-15 |
Family
ID=36129715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002612481A Abandoned CA2612481A1 (en) | 2005-07-20 | 2006-01-17 | Stable pharmaceutical composition comprising linezolid form iv |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070020329A1 (en) |
EP (1) | EP1749517B8 (en) |
JP (1) | JP2009501794A (en) |
CN (1) | CN101262853A (en) |
AT (1) | ATE400257T1 (en) |
AU (1) | AU2006277017A1 (en) |
CA (1) | CA2612481A1 (en) |
DE (1) | DE602006001699D1 (en) |
DK (1) | DK1749517T3 (en) |
ES (1) | ES2309920T3 (en) |
HK (1) | HK1097774A1 (en) |
IL (1) | IL188176A0 (en) |
PL (1) | PL1749517T3 (en) |
PT (1) | PT1749517E (en) |
WO (1) | WO2007018588A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007102082A1 (en) * | 2006-03-09 | 2007-09-13 | Glenmark Pharmaceuticals Limited | High oxazolidinone content solid dosage forms |
WO2011080570A2 (en) * | 2009-12-29 | 2011-07-07 | Micro Labs Limited | Extended release pharmaceutical composition comprising linezolid and process for preparing the same |
US9132132B2 (en) * | 2010-09-02 | 2015-09-15 | Hetero Research Foundation | Pharmaceutical compositions of linezolid |
CN102885788B (en) * | 2011-07-22 | 2016-06-29 | 重庆华邦制药有限公司 | A kind of Linezolid sheet of stable crystal form and preparation method thereof |
WO2013088389A1 (en) * | 2011-12-14 | 2013-06-20 | Alembic Pharmaceuticals Limited | Linezolid premix |
CN103099792B (en) * | 2012-12-10 | 2014-11-26 | 成都欣捷高新技术开发有限公司 | Preparation method of IV crystal linezolid tablets having high drug loading capacity and capable of quickly dissolving |
CN103893138B (en) * | 2012-12-28 | 2017-09-29 | 成都国为生物医药有限公司 | A kind of tablet containing linezolid form III |
CN104370846B (en) * | 2013-08-15 | 2017-04-12 | 杭州华东医药集团新药研究院有限公司 | Method for preparing linezolid IV crystal form |
CN104622831B (en) * | 2013-11-06 | 2018-06-22 | 江苏豪森药业集团有限公司 | A kind of oral tablet and preparation method thereof |
CN104173303B (en) * | 2014-08-14 | 2017-01-11 | 杭州华东医药集团新药研究院有限公司 | Linezolid-containing composition and preparation method thereof |
CN104586812A (en) * | 2014-12-25 | 2015-05-06 | 杭州华东医药集团新药研究院有限公司 | Composition containing linezolid as well as preparation method thereof |
EP3170864B1 (en) * | 2015-11-17 | 2018-10-17 | Borealis AG | High flow tpo composition with excellent balance in mechanical properties for automotive interior |
CN111675669A (en) * | 2020-05-15 | 2020-09-18 | 扬子江药业集团北京海燕药业有限公司 | Linezolid crystal form, preparation method and pharmaceutical composition thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
AR027261A1 (en) * | 2000-02-02 | 2003-03-19 | Upjohn Co | LINEZOLID CRYSTAL FORM II |
US6444813B2 (en) * | 2000-02-02 | 2002-09-03 | Pharmacia & Upjohn Company | Linezolid-crystal form II |
JP2003527424A (en) * | 2000-03-22 | 2003-09-16 | ファルマシア・アンド・アップジョン・カンパニー | Oxazolidinone tablet formulation |
US6514529B2 (en) * | 2000-03-22 | 2003-02-04 | Pharmacia & Upjohn Company | Oxazolidinone tablet formulation |
EP2902386B1 (en) * | 2003-10-16 | 2020-04-08 | Symed Labs Limited | A crystalline form of linezolid |
WO2006004922A1 (en) * | 2004-06-29 | 2006-01-12 | Teva Pharmaceutical Industries Ltd. | Crystalline form iv of linezolid |
-
2006
- 2006-01-17 JP JP2008522760A patent/JP2009501794A/en active Pending
- 2006-01-17 PL PL06250227T patent/PL1749517T3/en unknown
- 2006-01-17 AU AU2006277017A patent/AU2006277017A1/en not_active Abandoned
- 2006-01-17 DK DK06250227T patent/DK1749517T3/en active
- 2006-01-17 AT AT06250227T patent/ATE400257T1/en not_active IP Right Cessation
- 2006-01-17 EP EP06250227A patent/EP1749517B8/en not_active Revoked
- 2006-01-17 DE DE602006001699T patent/DE602006001699D1/en not_active Revoked
- 2006-01-17 WO PCT/US2006/001514 patent/WO2007018588A1/en active Application Filing
- 2006-01-17 CA CA002612481A patent/CA2612481A1/en not_active Abandoned
- 2006-01-17 ES ES06250227T patent/ES2309920T3/en active Active
- 2006-01-17 CN CNA2006800262811A patent/CN101262853A/en active Pending
- 2006-01-17 US US11/333,906 patent/US20070020329A1/en not_active Abandoned
- 2006-01-17 PT PT06250227T patent/PT1749517E/en unknown
-
2007
- 2007-05-21 HK HK07105361A patent/HK1097774A1/en not_active IP Right Cessation
- 2007-12-17 IL IL188176A patent/IL188176A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1749517B1 (en) | 2008-07-09 |
WO2007018588A1 (en) | 2007-02-15 |
WO2007018588A8 (en) | 2008-05-08 |
DK1749517T3 (en) | 2008-11-03 |
DE602006001699D1 (en) | 2008-08-21 |
AU2006277017A1 (en) | 2007-02-15 |
CN101262853A (en) | 2008-09-10 |
JP2009501794A (en) | 2009-01-22 |
EP1749517B8 (en) | 2008-10-22 |
ES2309920T3 (en) | 2008-12-16 |
EP1749517A1 (en) | 2007-02-07 |
ATE400257T1 (en) | 2008-07-15 |
PT1749517E (en) | 2008-09-29 |
HK1097774A1 (en) | 2007-07-06 |
IL188176A0 (en) | 2008-03-20 |
PL1749517T3 (en) | 2008-12-31 |
US20070020329A1 (en) | 2007-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2612481A1 (en) | Stable pharmaceutical composition comprising linezolid form iv | |
CA2635841A1 (en) | Stable pharmaceutical formulations of montelukast sodium | |
CA2662265A1 (en) | Imatinib compositions | |
EP2229938A1 (en) | Ezetimibe compositions | |
EA036701B1 (en) | Tablet pharmaceutical composition comprising anhydrous dasatinib | |
JP2009501214A (en) | Pharmaceutical composition containing clopidogrel bisulfate | |
US6514529B2 (en) | Oxazolidinone tablet formulation | |
CA2696977A1 (en) | Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof | |
WO2011101862A1 (en) | Stabilized fluconazole polymorph iii formulation | |
US9132132B2 (en) | Pharmaceutical compositions of linezolid | |
EP1265608B1 (en) | Oxazolidinone tablet formulation | |
EP1728513A2 (en) | Stable desloratadine compositions | |
WO2012176014A1 (en) | Imatinib mesylate oral pharmaceutical composition and process for preparation thereof | |
JP6883401B2 (en) | Azilsartan-containing tablets and methods for stabilizing azilsartan in tablets | |
EP1292598B1 (en) | Process for drying amoxicillin | |
US9227938B2 (en) | Pharmaceutical composition containing crystalline sorafenib tosylate | |
EP1776102A1 (en) | Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation | |
JP7101464B2 (en) | A method for improving the quality of azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof, and azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof and a method for producing the same. | |
EP2779999A2 (en) | Pharmaceutical formulations comprising atorvastatin and glimepiride | |
EP2875807B1 (en) | Tablet formulation of colesevelam | |
CA2877169A1 (en) | Pharmaceutical composition of moxifloxacin hydrochloride and preparation method | |
RU2018129198A (en) | PHARMACEUTICAL COMPOSITIONS | |
JP2023534186A (en) | A pharmaceutical composition comprising a diaminopyrimidine derivative or a pharmaceutically acceptable salt thereof, and a method for preparing the same | |
US20080102134A1 (en) | Controlled release color stable pharmaceutical dosage form of hmg-coa reductase inhibitors, free of alkalizing or buffering agents | |
WO2014007065A1 (en) | Solid pharmaceutical tablet, and method for producing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |